Timothy Noyes

Timothy Noyes is the President and CEO of Newleos Therapeutics, a Boston clinical-stage biotech that raised an oversubscribed $93.5M Series A to revive four neuropsychiatric compounds shelved by Roche. A Harvard-trained operator with three decades in biopharma, he has taken Proteon and Aerovate public, launched Renagel at GelTex/Genzyme, and built teams that carry molecules from bench to late-stage trials.